Literature DB >> 11469974

Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia.

Nelson Garcia1, Arun J. Sanyal.   

Abstract

Portal hypertensive gastropathy (PHG) causes both acute and chronic blood loss from the gastrointestinal tract in patients with portal hypertension. Gastric antral vascular ectasia (GAVE) is a distinct condition also associated with portal hypertension that can cause acute and chronic upper gastrointestinal blood loss. These conditions frequently, but not invariably, are diagnosed by upper endoscopy. Although they are fairly prevalent, only 15% to 20% of subjects experience symptomatic gastrointestinal blood loss. Acute gastrointestinal bleeding from PHG should first be treated with octreotide (100 mg bolus intravenously, followed by a 50 mg/h continuous intravenous infusion). If the bleeding does not stop or slow down appreciably within 24 to 48 hours, propranolol may be administered orally to those patients who are hemodynamically stable. Propranolol should be started at 40 mg/d orally in two divided doses. If the patient can tolerate the propranolol and is still bleeding, the dosage may be titrated up to the maximum tolerated amount. For those subjects who are unable to tolerate beta-blockers or continue to bleed despite beta-blocker therapy, transjugular intrahepatic portosystemic shunt (TIPS) is the next line of treatment. Portal decompressive surgery is reserved for those who are not candidates for TIPS and where the appropriate expertise is available. Prevention of chronic gastrointestinal blood loss from PHG should be attempted with beta-blockers, with the dosage titrated up to achieve a resting heart rate of approximately 60 beats per minute. In patients who do not respond to beta-blockers, a TIPS should be placed. The role of long-acting release octreotide in this setting is experimental. The primary treatment of actively bleeding GAVE as well as recurrent bleeding from GAVE is endoscopic ablation of the lesion using either argon plasma coagulation, neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, or heater probe. TIPS and beta-blockers are ineffective for the long-term prevention of recurrent bleeding from GAVE. For selected patients with severe recurrent bleeding or uncontrollable acute bleeding from GAVE, an antrectomy with Billroth I anastomosis may be considered.

Entities:  

Year:  2001        PMID: 11469974     DOI: 10.1007/s11938-001-0028-0

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  41 in total

1.  Endoscopic laser therapy for watermelon stomach.

Authors:  M J Bourke; R L Hope; P Boyd; P E Gillespie; M Ward; A E Cowen; S J Williams
Journal:  J Gastroenterol Hepatol       Date:  1996-09       Impact factor: 4.029

2.  The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract.

Authors:  G Nardone; A Rocco; T Balzano; G Budillon
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

3.  Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis.

Authors:  P S Kamath; M Lacerda; D A Ahlquist; M A McKusick; J C Andrews; D A Nagorney
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

4.  Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: an open pilot study.

Authors:  A Tran; J P Villeneuve; M Bilodeau; B Willems; D Marleau; D Fenyves; R Parent; G Pomier-Layrargues
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

Review 5.  Portal Hypertensive gastropathy.

Authors:  J M Piqué
Journal:  Baillieres Clin Gastroenterol       Date:  1997-06

Review 6.  Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis.

Authors:  J L Payen; P Calès; J J Voigt; S Barbe; C Pilette; L Dubuisson; H Desmorat; J P Vinel; A Kervran; J A Chayvialle
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

7.  Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt.

Authors:  M J Orloff; M S Orloff; S L Orloff; K S Haynes
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

8.  Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy.

Authors:  T Iwao; A Toyonaga; M Ikegami; K Oho; M Sumino; H Harada; M Sakaki; H Shigemori; T Aoki; K Tanikawa
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

Review 9.  Gallstones during octreotide therapy.

Authors:  R H Dowling; S H Hussaini; G M Murphy; G M Besser; J A Wass
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

10.  Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension.

Authors:  S K Sarin; D V Sreenivas; D Lahoti; A Saraya
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

View more
  1 in total

1.  Two for the price of one: a dual treatment benefit of long-acting octreotide in occult bleeding and diuretic intractable ascites.

Authors:  Bee Leng Lee; Jeff Turner; Joanna Hurley; John Green; Neil Hawkes; Ruth Alcolado
Journal:  Frontline Gastroenterol       Date:  2011-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.